Curated News
By: NewsRamp Editorial Staff
October 19, 2026
Pentixapharm Builds Global Evidence for Pentixafor PET in Primary Aldosteronism
TLDR
- Pentixapharm's Pentixafor PET gains international validation, positioning its Phase 3 PANDA study to capture the non-invasive primary aldosteronism subtyping market.
- Pentixafor PET/CT uses CXCR4-targeted imaging to detect one-sided adrenal disease, potentially replacing adrenal vein sampling for surgical triage.
- Pentixafor PET could spare hypertensive patients from invasive adrenal vein sampling, making diagnosis simpler and improving access to surgical cure.
- Independent studies across Europe, Asia, and Australia show Pentixafor PET reliably identifies unilateral primary aldosteronism, with patients preferring it over catheter procedures.
Impact - Why it Matters
This news matters because primary aldosteronism is a common but underdiagnosed cause of high blood pressure, and identifying patients with one-sided disease currently requires adrenal vein sampling—an invasive and technically demanding catheter procedure. If Pentixafor PET succeeds in the Phase 3 PANDA study, it could offer a non-invasive imaging alternative that helps guide the choice between surgery and lifelong medical therapy, potentially sparing many patients from an uncomfortable and burdensome examination. The independent data from Europe, Asia, and Australia strengthen the biological rationale for CXCR4-targeted imaging and may accelerate clinical adoption. Beyond hypertension, the same CXCR4 platform is being explored in hemato-oncology, including multiple myeloma and acute myeloid leukemia, where combined imaging and targeted bone marrow conditioning could improve stem cell transplantation outcomes. For patients and clinicians, this represents a step toward more precise, less invasive diagnostic pathways.
Summary
Pentixapharm Holding AG (Frankfurt Prime Standard: PTP), a Berlin-based clinical-stage biotechnology company, has announced new data presented at the Annual Congress of the European Association of Nuclear Medicine (EANM 2026) in Vienna that reinforce the potential of Pentixafor PET to non-invasively identify unilateral primary aldosteronism. The findings, which include the prospective PENTALON study from Paris and independent datasets from China, add to a consistent picture from studies on three continents, including the Monash study in Australia and the CASTUS study in the Netherlands, showing that Pentixafor PET can detect one-sided disease with high specificity and spare patients the invasive adrenal vein sampling procedure. According to the release, these results support the rationale for Pentixapharm’s pivotal Phase 3 PANDA study of [⁶⁸Ga]Ga-PentixaFor PET/CT, which was authorized by the FDA in June 2026 and granted Fast Track designation in July 2026. “Our pivotal Phase 3 study PANDA will answer a clear question: can we use a simple imaging procedure to identify the patients who can be helped by surgery, and spare them the invasive and burdensome catheter examination required today?” said Dr. Dirk Pleimes, Chief Executive Officer of Pentixapharm.
Beyond primary aldosteronism, the company highlighted multiple myeloma research, with investigators from CHU Nantes scheduled to present an interim analysis of [⁶⁸Ga]Ga-PentixaFor PET/CT for initial staging and treatment-response assessment. These findings feed into Pentixapharm’s broader theranostic strategy, including the planned Phase I/II PENTHERA program, which will investigate PentixaFor imaging to identify CXCR4-expressing disease and [⁹⁰Y]Y-PentixaTher for targeted bone marrow conditioning before stem cell transplantation in patients with multiple myeloma and acute myeloid leukemia. PentixaFor and PentixaTher are investigational radiopharmaceutical candidates.
The news release also notes that further congress information is available at https://eanm26.eanm.org/, and that Pentixapharm’s pipeline is built on CXCR4 targeting, with diagnostic and therapeutic programs in endocrine, cardiovascular, and oncological indications, as well as a next-generation antibody platform targeting CD24. The original release can be viewed on www.newmediawire.com.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Pentixapharm Builds Global Evidence for Pentixafor PET in Primary Aldosteronism
